A Randomized, Phase 1B, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Inhaled PUR003 on a Controlled Influenza Virus Challenge in Healthy Adult Subjects

Pulmatrix Inc.1 site in 1 country24 target enrollmentJuly 2009

ConditionsHealthy

InterventionsPUR003 Placebo

DrugsPUR003 Placebo

Overview

Phase: Phase 1
Intervention: PUR003
Conditions: Healthy
Sponsor: Pulmatrix Inc.
Enrollment: 24
Locations: 1
Primary Endpoint: Safety and tolerability of PUR003 as determined by incidence of adverse events (AEs); changes in physical examination, chest examination; pulmonary function; vital signs; electrocardiogram (ECG) and clinical laboratory assessments.
Status: Completed
Last Updated: 8 years ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Sites Similar Trials

Overview

Brief Summary

The objectives of the study are to demonstrate the effectiveness, safety and tolerability of multiple daily doses of inhaled PUR003, in comparison with placebo, in healthy adults experimentally inoculated with Influenza A/Wisconsin/67/2005 (H3N2) virus.

Registry

clinicaltrials.gov

Start Date

July 2009

End Date

October 2009

Last Updated

8 years ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

Pulmatrix Inc.

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Male and female subjects aged 18 to 45 years.
•In general good health determined by a screening evaluation ≤120 days prior to double-blind IMP administration and on the day of admittance to quarantine.
•Seronegative (NDA) for challenge virus.
•Have not been vaccinated for influenza virus since 2006 (as determined in the medical history) or had a known influenza infection in the current season, defined as in the last 12 months.

Exclusion Criteria

•Presence or evidence of significant acute or chronic, uncontrolled medical or psychiatric illness.
•Abnormal pulmonary function as evidenced by clinically significant abnormality in spirometry.
•Health care workers (including doctors, nurses, medical students and allied healthcare professionals) anticipated to have patient contact within two weeks of discharge from quarantine.
•Intending to travel (to countries for which vaccinations are recommended or where high risk of infections exists).
•Presence of household member or close contact (until 14 days after discharge from quarantine) who is: less than 3 years of age; has any known immunodeficiency; is receiving immunosuppressant medications; is undergoing or soon to undergo cancer chemotherapy within 28 days of challenge.
•Subjects with diagnosed emphysema or chronic obstructive pulmonary disease (COPD); elderly residing in a nursing home, affected by severe lung disease or medical condition; or a transplant (bone marrow or solid organ) organ recipient
•Subjects with any history of asthma, COPD, pulmonary hypertension, reactive airway disease, or any chronic lung condition of any aetiology.
•Regular daily smokers during the 6 months prior to study entry or those who have a significant history of any tobacco use at any time (≥ total 10 pack year history = one pack a day for 10 years).
•Presence of any febrile illness or symptoms of upper or lower tract respiratory infection in the 28 days prior to viral inoculation (such subjects may be re-evaluated for enrolment after resolution of the illness).
•Receipt of any investigational drug within 3 months, or prior participation in a clinical trial of any influenza vaccine or medication within 1 year of participation.

Arms & Interventions

PUR003

Intervention: PUR003

Placebo

Intervention: Placebo

Outcomes

Primary Outcomes

Safety and tolerability of PUR003 as determined by incidence of adverse events (AEs); changes in physical examination, chest examination; pulmonary function; vital signs; electrocardiogram (ECG) and clinical laboratory assessments.

Time Frame: Day 6

Secondary Outcomes

Quantitative viral shedding from nasal viral inoculation until day 6(Day 0 to day 6)
Subjected-reported symptom scores assessed both individually and as a composite score evaluating severity overall and at the time of peak symptom score(Day 6 of study)
Change in bioaerosol output with treatment and after viral inoculation(Day -2 to day 6)